Solid Biosciences (SLDB) recently disclosed that the company plans to hold a follow-up meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2026, aiming to obtain further guidance on the potential accelerated approval pathway for its gene therapy SGT-003.

This meeting will focus on discussing whether SGT-003 meets the eligibility criteria for accelerated approval and what regulatory requirements need to be fulfilled. The company hopes to clarify subsequent clinical development and application strategies through in-depth communication with the FDA, paving the way for this potential therapy targeting Duchenne Muscular Dystrophy (DMD). The accelerated approval pathway typically allows drugs for serious diseases to be approved earlier based on surrogate endpoints or intermediate clinical endpoints, in order to meet patient needs more quickly. Solid Biosciences’ actions demonstrate its determination to actively advance the development of SGT-003.